BBIO vs. HIMS
BBIO (BridgeBio Pharma, Inc.) and HIMS (Hims & Hers Health, Inc.) are both stocks. Both are in the Healthcare sector — BBIO in Biotechnology, HIMS in Drug Manufacturers - Specialty & Generic. Over the past 5 years, BBIO returned 2.90%/yr vs 25.12%/yr for HIMS. At a 0.26 correlation, their price movements are largely independent.
Performance
BBIO vs. HIMS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BBIO achieves a -10.28% return, which is significantly lower than HIMS's 1.51% return.
BBIO
- 1D
- -0.42%
- 1M
- -0.71%
- YTD
- -10.28%
- 6M
- -10.17%
- 1Y
- 62.73%
- 3Y*
- 63.65%
- 5Y*
- 2.90%
- 10Y*
- —
HIMS
- 1D
- -1.73%
- 1M
- 38.78%
- YTD
- 1.51%
- 6M
- -5.29%
- 1Y
- -21.49%
- 3Y*
- 57.60%
- 5Y*
- 25.12%
- 10Y*
- —
BBIO vs. HIMS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | -10.28% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 102.88% | 34.29% |
HIMS Hims & Hers Health, Inc. | 1.51% | 34.28% | 171.69% | 38.85% | -2.14% | -55.14% | 47.47% | 1.23% |
Correlation
The correlation between BBIO and HIMS is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.30 |
Correlation (All Time) Calculated using the full available price history since Sep 13, 2019 | 0.26 |
Fundamentals
BBIO:
$13.37B
HIMS:
$7.53B
BBIO:
-$3.76
HIMS:
-$0.05
BBIO:
23.43
HIMS:
3.41
BBIO:
$566.04M
HIMS:
$2.37B
BBIO:
$538.20M
HIMS:
$1.70B
BBIO:
-$602.24M
HIMS:
$16.04M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBIO vs. HIMS — Risk / Return Rank
BBIO
HIMS
BBIO vs. HIMS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Hims & Hers Health, Inc. (HIMS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BBIO | HIMS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.59 | ||
| Sortino ratioReturn per unit of downside risk | +1.75 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.03 | +0.24 |
| Calmar ratioReturn relative to maximum drawdown | 3.11 | -0.28 | +3.39 |
| Martin ratioReturn relative to average drawdown | 7.28 | -0.45 | +7.73 |
Loading charts...
Drawdowns
BBIO vs. HIMS - Drawdown Comparison
The maximum BBIO drawdown since its inception was -92.80%, which is greater than HIMS's maximum drawdown of -87.29%. Use the drawdown chart below to compare losses from any high point for BBIO and HIMS.
Loading charts...
Drawdown Indicators
| BBIO | HIMS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.80% | -87.29% | -5.51% |
Max Drawdown (1Y)Largest decline over 1 year | -20.25% | -78.06% | +57.81% |
Max Drawdown (3Y)Largest decline over 3 years | -49.08% | -78.88% | +29.80% |
Max Drawdown (5Y)Largest decline over 5 years | -91.89% | -78.88% | -13.01% |
Current DrawdownCurrent decline from peak | -14.12% | -52.05% | +37.93% |
Average DrawdownAverage peak-to-trough decline | -45.66% | -43.26% | -2.40% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.64% | 48.15% | -39.51% |
Volatility
BBIO vs. HIMS - Volatility Comparison
The current volatility for BridgeBio Pharma, Inc. (BBIO) is 9.14%, while Hims & Hers Health, Inc. (HIMS) has a volatility of 23.50%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than HIMS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BBIO | HIMS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.14% | 23.50% | -14.36% |
Volatility (6M)Calculated over the trailing 6-month period | 34.37% | 69.23% | -34.86% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.41% | 97.66% | -51.25% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 85.95% | 83.58% | +2.37% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.65% | 77.37% | +6.28% |
Dividends
BBIO vs. HIMS - Dividend Comparison
Neither BBIO nor HIMS has paid dividends to shareholders.
Financials
BBIO vs. HIMS - Financials Comparison
This section allows you to compare key financial metrics between BridgeBio Pharma, Inc. and Hims & Hers Health, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BBIO vs. HIMS - Profitability Comparison
BBIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.
HIMS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a gross profit of 396.79M and revenue of 608.10M. Therefore, the gross margin over that period was 65.3%.
BBIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.
HIMS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported an operating income of -78.32M and revenue of 608.10M, resulting in an operating margin of -12.9%.
BBIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.
HIMS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a net income of -92.12M and revenue of 608.10M, resulting in a net margin of -15.2%.
Frequently Asked Questions
BBIO and HIMS have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
HIMS has higher volatility (23.50%) compared to BBIO (9.14%). In terms of maximum drawdown, BBIO dropped -92.80% vs HIMS's -87.29%.
BBIO currently has the higher Sharpe Ratio (1.36 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BBIO and HIMS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer